Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tricyclic antidepressants effective for headaches, but comparative trials would be more convincing

This article was originally published in Scrip

Executive Summary

Tricyclic antidepressants have been used for treating headaches as an unlicensed indication since the 1960s (as well as being recommended for this in European and US neurology clinical guidelines), but their role was given a further boost in a meta-analysis study published in the BMJ last week. Despite evidence from the meta-analysis that tricyclics are effective preventative treatments for headache and migraine, the real clinical proof of their effectiveness is unlikely to be generated by the pharmaceutical industry, commentators says.

You may also be interested in...

US FDA head Hamburg declares no one can inspect world on its own

The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.

FDA's Hamburg declares no one can "inspect world on its own" for poor quality medicines

It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.

Pharma and MSF agree on competition for cheap vaccines, but differ on pricing

Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts